Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease‐Modifying Therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 2151-4658|67|5|731-736

ISSN： 2151-464x

Source： ARTHRITIS CARE AND RESEARCH, Vol.67, Iss.5, 2015-05, pp. : 731-736

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1671-1678

John Wiley & Sons Inc

Access to resources Recommend Favorite

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

By Kielhorn Adrian   Porter Duncan   Diamantopoulos Alexander   Lewis Gavin  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2639-2650

Informa Healthcare

Access to resources Recommend Favorite

Use and Spending for Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 9, 2015-09 ,pp. : 1210-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Differential risk of herpes zoster infection with biologic agent use in rheumatoid arthritis: comment on the article by Yun et al

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 7, 2015-07 ,pp. : 1041-1041

John Wiley & Sons Inc

Access to resources Recommend Favorite

Disease‐Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 457-466

John Wiley & Sons Inc

Access to resources Recommend Favorite